Dalton Smart
Algemeen Directeur bij HARPOON THERAPEUTICS, INC.
Vermogen: 578 828 $ op 30-04-2024
Actieve functies van Dalton Smart
| Bedrijven | Functie | Begin | Einde |
|---|---|---|---|
| MERCK & CO., INC. | Comptroller/Controller/Auditor | 04-12-2023 | - |
| Corporate Officer/Principal | 01-09-2023 | 04-12-2023 | |
| HARPOON THERAPEUTICS, INC. | Algemeen Directeur | - | - |
| Junior Achievement of New Jersey, Inc. | Directeur/Bestuurslid | - | - |
Loopbaan van Dalton Smart
Statistieken
Internationaal
| Verenigde Staten | 4 |
Operationeel
| Director/Board Member | 1 |
| Comptroller/Controller/Auditor | 1 |
| Corporate Officer/Principal | 1 |
Sectoraal
| Health Technology | 3 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| MERCK & CO., INC. | Health Technology |
| Bedrijven in privébezit | 2 |
|---|---|
| Junior Achievement of New Jersey, Inc. | |
Harpoon Therapeutics, Inc.
 Harpoon Therapeutics, Inc. BiotechnologyHealth Technology Harpoon Therapeutics, Inc. is a clinical-stage immunotherapy company, which engages in the development of antibodies. It focuses on the research of novel class of T cell engagers that harness the power of the body’s immune system to treat patients suffering from cancer and other diseases. The firm utilizes its proprietary Tri-specific T cell Activating Construct platform to create a pipeline of novel TriTACs for the treatment of solid tumors and hematologic malignancies. The company was founded by Patrick A. Baeuerle, Luke B. Evnin, and Jeanmarie Guenot on March 19, 2015 and is headquartered in South San Francisco, CA. | Health Technology |
- Beurs
- Insiders
- Dalton Smart
- Ervaring
